Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage May 15, 2018
Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 26, 2018
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting Feb 12, 2018
Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma Feb 8, 2018
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting Feb 5, 2018
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™) Jan 29, 2018
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting Jan 22, 2018
